NDUFS4 and Leigh syndrome: Treatment options for LS patients are very limited; however, promising pre-clinical studies using the same germline Ndufs4−/−mouse model have identified potential new therapies to alleviate LS pathologies, including rapamycin [31], chronic hypoxia [32], supplementation of NAD+ [24], and microglial ablation [33].